Alastair M Thompson

List of Publications by Year
in descending order

85 papers	9,475 citations	186265 28 h-index	60623 81 g-index
87 all docs	87 docs citations	87 times ranked	15087 citing authors

#	Article	IF	Citations
1	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	27.8	1,760
2	Telomere reduction in human colorectal carcinoma and with ageing. Nature, 1990, 346, 866-868.	27.8	1,612
3	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. New England Journal of Medicine, 2016, 375, 717-729.	27.0	1,427
4	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 2017, 23, 517-525.	30.7	769
5	Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Molecular Cell, 2018, 71, 606-620.e7.	9.7	491
6	Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Practical Radiation Oncology, 2017, 7, 73-79.	2.1	483
7	The topography of mutational processes in breast cancer genomes. Nature Communications, 2016, 7, 11383.	12.8	235
8	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, 2017, 543, 714-718.	27.8	229
9	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. JAMA Oncology, 2015, 1, 931.	7.1	216
10	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncology, The, 2021, 22, 476-488.	10.7	179
11	Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer, 2019, 121, 285-292.	6.4	168
12	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology, 2019, 37, 2206-2216.	1.6	152
13	Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. Journal of Clinical Oncology, 2020, 38, 388-394.	1.6	151
14	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	12.8	119
15	The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. European Journal of Cancer, 2011, 47, 2742-2749.	2.8	99
16	The circular RNome of primary breast cancer. Genome Research, 2019, 29, 356-366.	5.5	85
17	Effect of Metformin vs Placebo on Invasive Diseaseâ€“Free Survival in Patients With Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 1963.	7.4	81
18	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nature Genetics, 2017, 49, 341-348.	21.4	75

#	Article	IF	Citations
19	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	5.5	69
20	A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Communications, 2018, 9, 1107.	12.8	63
21	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. European Journal of Surgical Oncology, 2018, 44, 429-435.	1.0	62
22	A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. BMJ Open, 2014, 4, e005285-e005285.	1.9	59
23	SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Annals of Surgical Oncology, 2019, 26, 3510-3516.	1.5	47
24	Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer. Clinical Cancer Research, 2014, 20, 2508-2515.	7.0	45
25	Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. British Journal of Clinical Pharmacology, 2017, 83, 653-663.	2.4	44
26	Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. European Journal of Cancer, 2021, 144, 269-280.	2.8	37
27	Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays. British Journal of Cancer, 2015, 113, 1075-1080.	6.4	33
28	Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis . Cancer Management and Research, 2019, Volume 11, 1433-1442.	1.9	32
29	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal of Clinical Oncology, 2019, 37, 3484-3492.	1.6	30
30	Longitudinal analysis of patientâ€reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated wholeâ€breast irradiation. Cancer, 2016, 122, 2886-2894.	4.1	29
31	Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. British Journal of Cancer, 2021, 124, 1009-1017.	6.4	29
32	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer, 2020, 122, 258-265.	6.4	28
33	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Modern Pathology, 2019, 32, 1257-1262.	5.5	27
34	Macroscopic handling and reporting of breast cancer specimens preâ€and postâ€neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology, 2015, 67, 279-293.	2.9	26
35	Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer. British Journal of Cancer, 2021, 125, 209-219.	6.4	26
36	Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget, 2015, 6, 21685-21703.	1.8	24

#	Article	IF	Citations
37	Randomised controlled trial of exercise to prevent shoulder problems in women undergoing breast cancer treatment: study protocol for the prevention of shoulder problems trial (UK PROSPER). BMJ Open, 2018, 8, e019078.	1.9	22
38	Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. Oncologist, 2017, 22, 394-401.	3.7	21
39	Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?. Cancer Imaging, 2019, 19, 67.	2.8	19
40	Functional Tumor Volume by Fast Dynamic<scp>Contrastâ€Enhanced MRI</scp>for Predicting Neoadjuvant Systemic Therapy Response in<scp>Tripleâ€Negative</scp>Breast Cancer. Journal of Magnetic Resonance Imaging, 2021, 54, 251-260.	3.4	18
41	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. Annals of Surgery Open, 2020, 1, e008.	1.4	18
42	Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation. BMJ, The, 2021, 375, e066542.	6.0	18
43	Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Research, 2018, 20, 27.	5.0	17
44	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
45	Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?. European Journal of Cancer, 2015, 51, 907-914.	2.8	15
46	A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. BMC Cancer, 2016, 16, 745.	2.6	14
47	Imaging features of triple-negative breast cancers according to androgen receptor status. European Journal of Radiology, 2019, 114, 167-174.	2.6	14
48	âˆ†Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stemâ€like cells in human ER⁺ and HER2⁺ breast cancers. Journal of Pathology: Clinical Research, 2020, 6, 83-93.	3.0	13
49	A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. European Journal of Radiology, 2022, 149, 110220.	2.6	13
50	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. Breast, 2022, 61, 145-155.	2.2	12
51	Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy. British Journal of Radiology, 2018, 91, 20180123.	2.2	11
52	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. Npj Breast Cancer, 2021, 7, 51.	5.2	11
53	Observational cohort study in older women with early breast cancer: Use of radiation therapy and impact on health-related quality of life and mortality. Radiotherapy and Oncology, 2021, 161, 166-176.	0.6	11
54	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. Journal of Clinical Oncology, 2020, 38, 1186-1197.	1.6	10

#	Article	IF	Citations
55	Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Research and Treatment, 2021, 185, 1-12.	2.5	10
56	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	7.0	10
57	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. Npj Breast Cancer, 2020, 6, 60.	5.2	9
58	Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. Clinical Cancer Research, 2020, 26, 1977-1984.	7.0	9
59	Low-risk DCIS. What is it? Observe or excise?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 21-32.	2.8	9
60	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clinical Cancer Research, 2021, 27, 6115-6123.	7.0	9
61	Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT. Health Technology Assessment, 2022, 26, 1-124.	2.8	9
62	Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?. American Journal of Surgery, 2018, 215, 693-698.	1.8	7
63	Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Advances in Radiation Oncology, 2020, 5, 824-833.	1.2	7
64	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. Breast, 2020, 50, 95-103.	2.2	7
65	BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Academic Radiology, 2022, 29, S35-S41.	2.5	7
66	RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. Journal of the National Cancer Institute, 2015, 107, djv065-djv065.	6.3	6
67	Effects of Standard Treatments for Ductal Carcinoma In Situâ€”Making Informed Choices. JAMA Oncology, 2016, 2, 396.	7.1	6
68	â€œIs it cancer or not?â€•A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. Cancer, 2022, 128, 1676-1683.	4.1	6
69	Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in <scp>Tripleâ€Negative</scp> Breast Cancer. Journal of Magnetic Resonance Imaging, 2022, 56, 1901-1909.	3.4	6
70	Breast conservation therapy versus mastectomy for breast cancer. Lancet Oncology, The, 2020, 21, 493-494.	10.7	5
71	Cancer Antigen 15-3/Mucin 1â€‚Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5
72	Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?. Surgical Oncology Clinics of North America, 2018, 27, 69-80.	1.5	4

#	Article	IF	Citations
73	Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. European Journal of Radiology, 2020, 130, 109170.	2.6	4
74	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). BMJ Open, 2022, 12, e058050.	1.9	4
75	Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438). Cancer Research, 2022, 82, GS1-08-GS1-08.	0.9	4
76	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers, 2022, 14, 1323.	3.7	4
77	The time-varying effect of radiotherapy after breast-conserving surgery for DCIS. Breast Cancer Research and Treatment, 2019, 178, 221-230.	2.5	3
78	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. JAMA Oncology, 2020, 6, 1117.	7.1	3
79	Reply to â€œComment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Projectâ€• British Journal of Cancer, 2021, 124, 1463-1464.	6.4	2
80	Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound in Medicine and Biology, 2022, , .	1.5	2
81	Abstract PD6-06: Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients. , 2021, , .		1
82	Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT. Programme Grants for Applied Research, 2022, 10, 1-114.	1.0	1
83	Intraoperative Radiotherapy: Is it Ready for Prime Time?. Current Breast Cancer Reports, 2015, 7, 15-21.	1.0	0
84	Abstract P3-18-10: Current options and future perspectives for breast margin assessment in clinical practice. Cancer Research, 2022, 82, P3-18-10-P3-18-10.	0.9	0
85	Abstract P1-22-01: Predictors of inaccurate pre-operative size assessment of screen detected DCIS and impact on recurrence rates. Cancer Research, 2022, 82, P1-22-01-P1-22-01.	0.9	0